Cozad Asset Management Inc. Sells 5,003 Shares of Novo Nordisk A/S (NYSE:NVO)

Cozad Asset Management Inc. trimmed its holdings in Novo Nordisk A/S (NYSE:NVO) by 20.9% in the 4th quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 18,898 shares of the company’s stock after selling 5,003 shares during the quarter. Cozad Asset Management Inc.’s holdings in Novo Nordisk A/S were worth $1,626,000 as of its most recent SEC filing.

A number of other institutional investors have also added to or reduced their stakes in NVO. GWN Securities Inc. bought a new position in shares of Novo Nordisk A/S during the fourth quarter worth $268,000. Glenview Trust co boosted its holdings in shares of Novo Nordisk A/S by 55.8% during the 4th quarter. Glenview Trust co now owns 20,566 shares of the company’s stock valued at $1,769,000 after purchasing an additional 7,369 shares during the last quarter. Patten & Patten Inc. TN grew its holdings in shares of Novo Nordisk A/S by 480.5% in the fourth quarter. Patten & Patten Inc. TN now owns 21,855 shares of the company’s stock valued at $1,880,000 after purchasing an additional 18,090 shares in the last quarter. Hutchinson Capital Management CA grew its holdings in Novo Nordisk A/S by 0.3% during the 4th quarter. Hutchinson Capital Management CA now owns 175,651 shares of the company’s stock valued at $15,109,000 after purchasing an additional 563 shares during the last quarter. Finally, Avalon Trust Co increased its stake in Novo Nordisk A/S by 29.0% in the fourth quarter. Avalon Trust Co now owns 3,061 shares of the company’s stock worth $263,000 after purchasing an additional 689 shares during the period. 11.54% of the stock is owned by hedge funds and other institutional investors.

Novo Nordisk A/S Stock Up 4.0 %

Novo Nordisk A/S stock opened at $80.26 on Tuesday. The company has a quick ratio of 0.55, a current ratio of 0.74 and a debt-to-equity ratio of 0.62. The firm has a market cap of $360.15 billion, a P/E ratio of 24.39, a P/E/G ratio of 0.90 and a beta of 0.42. The business has a fifty day moving average of $83.85 and a two-hundred day moving average of $102.39. Novo Nordisk A/S has a twelve month low of $73.80 and a twelve month high of $148.15.

Novo Nordisk A/S (NYSE:NVO) last issued its quarterly earnings data on Wednesday, February 5th. The company reported $0.91 earnings per share for the quarter, topping analysts’ consensus estimates of $0.88 by $0.03. Novo Nordisk A/S had a return on equity of 84.68% and a net margin of 34.81%. On average, analysts forecast that Novo Nordisk A/S will post 3.84 earnings per share for the current fiscal year.

Novo Nordisk A/S Increases Dividend

The company also recently disclosed a semi-annual dividend, which will be paid on Tuesday, April 8th. Stockholders of record on Monday, March 31st will be given a $0.7874 dividend. The ex-dividend date is Monday, March 31st. This represents a dividend yield of 1.2%. This is an increase from Novo Nordisk A/S’s previous semi-annual dividend of $0.51. Novo Nordisk A/S’s payout ratio is presently 47.72%.

Wall Street Analyst Weigh In

A number of research firms have recently commented on NVO. Morgan Stanley initiated coverage on shares of Novo Nordisk A/S in a report on Wednesday, February 12th. They issued an “equal weight” rating on the stock. StockNews.com upgraded shares of Novo Nordisk A/S from a “buy” rating to a “strong-buy” rating in a research note on Thursday, March 13th. Stifel Nicolaus lowered Novo Nordisk A/S from a “buy” rating to a “hold” rating in a report on Monday, March 3rd. Kepler Capital Markets raised Novo Nordisk A/S from a “hold” rating to a “buy” rating in a research note on Thursday, March 13th. Finally, BMO Capital Markets decreased their target price on Novo Nordisk A/S from $156.00 to $105.00 and set an “outperform” rating for the company in a research report on Monday, December 23rd. Three investment analysts have rated the stock with a hold rating, six have issued a buy rating and two have given a strong buy rating to the stock. According to data from MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and a consensus price target of $145.25.

About Novo Nordisk A/S

Novo Nordisk A/S, together with its subsidiaries, engages in the research and development, manufacture, and distribution of pharmaceutical products in Europe, the Middle East, Africa, Mainland China, Hong Kong, Taiwan, North America, and internationally. It operates in two segments, Diabetes and Obesity Care, and Rare Disease.